#USA #AI Solutions #Bethesda #SOPHiA GENETICS #Precision for Medicine

Transforming Biopharma: The Power of Partnership

In a groundbreaking collaboration, Precision for Medicine, a leader in drug development, has partnered with SOPHiA GENETICS to elevate its biopharma services. This strategic alliance, announced on April 8, 2025, aims to enhance biomarker discovery using the innovative SOPHiA DDM™ platform and its capabilities in liquid biopsy technology. This partnership signifies a major step forward in accelerating drug development and delivering tailored therapies more efficiently to patients in need.

Streamlining Drug Development

Through the integration of the SOPHiA DDM™ platform, Precision for Medicine will apply advanced artificial intelligence (AI) analytics to complex multimodal datasets, which include genomic, radiomic, and clinical data. This integration enhances the ability of biopharma companies to identify optimal patient populations for their clinical trials, thereby accelerating biomarker discovery and improving diagnostics. This is particularly crucial in the fields of oncology, rare diseases, and genetic disorders, where understanding specific genomic attributes can significantly enhance treatment efficacy.

As Darren Davis, PhD, Senior Vice President at Precision for Medicine, states, "We're thrilled to partner with SOPHiA GENETICS, enhancing our service offerings to provide biopharma companies with effective tools for patient identification in clinical trials. The incorporation of AI-powered algorithms allows us to systematically pinpoint biomarkers and genomic signals that are instrumental in developing targeted therapies. This ultimately leads to expedited patient enrollment, reduced trial costs, and faster market introduction of novel therapies.”

Enhanced Quantum for Clinical Trials

A significant facet of this partnership is the MSK-ACCESS® test, which is powered by the SOPHiA DDM™ platform. This innovative liquid biopsy test will now be available through Precision for Medicine and is already deployed globally with AstraZeneca’s support. The data generated from this test will facilitate improved retrospective analysis of clinical trial results, as well as fine-tune patient stratification methodologies. As a result, biopharma companies can enhance their clinical trial designs by gaining a deeper understanding of patient responses to existing treatments.

With this evidence-based approach, organizations can refine their drug development strategies and optimize patient recruitment efforts, yielding crucial insights into therapeutic efficacy in practical, real-world environments.

Comprehensive Solutions under One Roof

The partnership empowers biopharma companies with a one-stop solution that integrates wet lab services with data analysis and clinical trial support. This consolidated approach allows clients to collaborate with a single provider, ensuring that both Precision for Medicine and SOPHiA GENETICS align their efforts towards delivering comprehensive support for drug development initiatives.

Ross Muken, President at SOPHiA GENETICS, emphasizes, "Our collaboration with Precision for Medicine enables us to broaden the reach and efficacy of our SOPHiA DDM™ platform. Merging our AI-driven platform with Precision for Medicine's advanced clinical trial solutions equips biopharma companies with real-time insights across the clinical trial continuum, ultimately accelerating the market entry of precision therapies.”

Delivering Competitive Advantages

The union of Precision for Medicine's renowned expertise in clinical trials and biomarker testing with SOPHiA GENETICS' innovative AI genomic analysis tools represents a significant leap forward for biopharma clients. It allows for a seamless progression from preclinical research to market readiness, giving clients an edge in the fast-paced biopharma landscape.

This partnership aims to revolutionize precision medicine, equipping biopharma companies with the means to grasp patient genomic information and devise personalized treatment protocols for intricate medical issues. By tailoring therapies to specific genomic profiles, the collaboration seeks to enhance patient outcomes, satisfaction, and the market viability of new drugs.

About Precision for Medicine

Precision for Medicine is a pioneering clinical research organization that specializes in the use of biomarkers for the effective targeting of patient treatments. With a commitment to transforming clinical research through integrated knowledge and data intelligence, the organization addresses the pressing need for faster clinical development and regulatory approval processes.

About SOPHiA GENETICS

SOPHiA GENETICS is a leading cloud-native healthcare technology company focused on enabling data-driven medicine through AI services. Their innovative SOPHiA DDM™ platform provides real-time insights, fostering collaborations across hospitals, laboratories, and biopharma entities worldwide.

This strategic alliance between Precision for Medicine and SOPHiA GENETICS represents not just a partnership, but a concerted effort to enhance the capabilities of biopharma services, establishing a more responsive, data-driven framework for clinical evolution in medicine.